

## FORM 5

### **QUARTERLY LISTING STATEMENT**

Name of Listed Issuer: **United Lithium Corp.** (the “Issuer”)

---

Trading Symbol: **ULTH**

---

This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

#### **General Instructions**

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

#### **SCHEDULE A: FINANCIAL STATEMENTS**

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

**Unaudited condensed interim consolidated financial statements for the three and six months ended January 31, 2024, as filed with the securities regulatory authorities are attached to this Form 5 as Appendix “A”.**

#### **SCHEDULE B: SUPPLEMENTARY INFORMATION**

The supplementary information set out below must be provided when not included in Schedule A.

## 1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

All related party transactions have been disclosed in the Issuer's financial statements for the interim period ended January 31, 2024. Please refer to Note 10 to the unaudited condensed interim consolidated financial statements for the three and six months ended January 31, 2024, attached hereto as Appendix "A". For information supplementary to that contained in the notes to the unaudited condensed interim consolidated financial statements with respect to related party transactions, please refer to the Management Discussion and Analysis ("MD&A") for the three and six months ended January 31, 2024, as filed with the securities regulatory authorities and attached to this Form 5 as Appendix "B".

## 2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

All securities issued and options granted, if any, by the Issuer have been disclosed in the Issuer's financial statement notes for the interim period ended January 31, 2024.

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
N/A - None								
N/A - None								

- (b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of
------	--------	---	--	----------------	-------------	-------------------------

						<b>Grant</b>
January 23, 2024	100,000	Anoop Prihar (Officer of Company)		\$1.05	January 23, 2029	\$0.415

**3. Summary of securities as at the end of the reporting period.**

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

<b>Description</b>	<b>Number Authorized</b>	<b>Par Value</b>
Common Shares	Unlimited	Without Par Value

- (b) number and recorded value for shares issued and outstanding,

<b>Description</b>	<b>Number Issued and Outstanding<sup>1</sup></b>	<b>Value</b>
Common Shares	41,074,388	\$16,224,383

- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

<b>Description</b>	<b>Number Outstanding<sup>1</sup></b>	<b>Exercise Price<sup>1</sup></b>	<b>Expiry Date</b>
Share Purchase Options	133,333	\$1.92	November 6, 2025
Share Purchase Options	83,333	\$3.54	February 19, 2026
Share Purchase Options	283,333	\$1.80	December 23, 2026
Share Purchase Options	1,333,333	\$1.05	March 14, 2028
Share Purchase Options	388,333	\$1.05	June 20, 2028
Share Purchase Options	200,000	\$1.05	October 2, 2028
Share Purchase Options	100,000	\$1.05	January 23, 2029
<b>TOTAL</b>	<b>2,521,665</b>		

<b>Description</b>	<b>Number Outstanding<sup>1</sup></b>	<b>Exercise Price<sup>1</sup></b>	<b>Expiry Date</b>
Common Share Purchase Warrants	133,333	\$1.47	April 29, 2024
Common Share Purchase Warrants	16,666,667	\$0.75	March 6, 2025
<b>TOTAL:</b>	<b>16,800,000</b>		

<sup>1</sup> A 3 for 1 share consolidation was completed on December 27, 2023 (the "Consolidation"). As a result of the Consolidation, all of the Company's outstanding common shares, share purchase options and share purchase warrants were adjusted by the Consolidation ratio and the respective exercise prices of those outstanding option and warrants were adjusted accordingly.

- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

Description	Number	Number Released During the Period
N/A - None	N/A - None	N/A - None

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name	Position
Scott Eldridge	President, Chief Executive Officer and Director
Chris Cairns	Chief Financial Officer
Rona Sellers	Vice President Compliance and Corporate Secretary
Anoop Prihar	Vice President Corporate Development
Michael Kobler	Director
Robert Schafer	Director
Iain Scarr	Director
Henrik Lundin	Director

#### SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

**Management Discussion and Analysis (“MD&A”) for the three and six months ended January 31, 2024, attached to this Form 5 as Appendix “B”.**

*[The remainder of this page is intentionally left blank. Signature page follows.]*

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated: March 28, 2024

Chris Cairns

Name of Director or Senior Officer

/s/ Chris Cairns

Signature

Chief Financial Officer

Official Capacity

<b>Issuer Details</b>	For Quarter Ended	Date of Report
Name of Issuer United Lithium Corp.	January 31, 2024	YYYY/MM/DD 2024/03/28
Issuer Address Suite 710 – 1030 Georgia St. W		
City/Province/Postal Code Vancouver, British Columbia, V6E 2Y3	Issuer Fax No. Not applicable	Issuer Telephone No. 604-428-6128
Contact Name Chris Cairns	Contact Position Chief Financial Officer	Contact Telephone No. 604-428-6128
Contact Email Address <a href="mailto:chris@unitedlithium.com">chris@unitedlithium.com</a>	Web Site Address <a href="https://unitedlithiumcorp.com">https://unitedlithiumcorp.com</a>	